Back to top
more

Fortrea Holdings Inc. (FTRE)

(Delayed Data from NSDQ)

$6.58 USD

6.58
2,854,172

+0.02 (0.30%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $6.58 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Fortrea Holdings Inc. (FTRE) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of +216.67% and +12.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of -25.00% and -57.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Exelixis, Inc. (EXEL) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Exelixis (EXEL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

FTRE vs. ILMN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

FTRE vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

Fortrea Holdings Inc. (FTRE) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of 128.57% and 6.79%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Illumina (ILMN) delivered earnings and revenue surprises of 1.04% and 0.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Oculis Holding AG (OCS) Q1 Earnings Expected to Decline

by Zacks Equity Research

Oculis Holding AG (OCS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Analysts Estimate Fortrea Holdings Inc. (FTRE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Fortrea Holdings Inc. (FTRE) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of -50% and 0.63%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fortrea Holdings Inc. (FTRE) Lags Q3 Earnings Estimates

by Zacks Equity Research

Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of -14.81% and 0.12%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Puma Biotech (PBYI) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 28.57% and 12.88%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of 53.85% and 0.46%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

BioXcel Therapeutics (BTAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 8.25% and 1.56%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Do Options Traders Know Something About Fortrea Holdings (FTRE) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Fortrea Holdings (FTRE) stock based on the movements in the options market lately.

Zacks Equity Research

Fortrea Holdings Inc. (FTRE) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of -142.86% and 3.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

InflaRx (IFRX) delivered earnings and revenue surprises of -23.81% and 83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Caribou Biosciences, Inc. (CRBU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Caribou Biosciences (CRBU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: Fortrea Holdings Inc. (FTRE) Q2 Earnings Expected to Decline

by Zacks Equity Research

Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Ensign Group (ENSG) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Ensign Group (ENSG) delivered earnings and revenue surprises of 2.33% and 1.97%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Do Options Traders Know Something About Fortrea (FTRE) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Fortrea (FTRE) stock based on the movements in the options market lately.

Zacks Equity Research

Company News for Mar 12, 2024

by Zacks Equity Research

Companies in The News Are: LEGN, BA, ALK, FTRE, AVGO.

Zacks Equity Research

Cognizant (CTSH), Microsoft Team Up to Streamline Healthcare

by Zacks Equity Research

Cognizant (CTSH) and Microsoft join forces to transform healthcare admin with generative AI integration on TriZetto.